2021 Revenues ($USD) : $46,940,864,000
2021 Revenues (foreign currencies) : £34,114,000,000
2021 R&D spend : $6,571,776,000
2021 Number of Employees : 90,096
Fiscal Year End : 12/31/2021
Leader : CEO Dame Emma Walmsley

In 2021, GlaxoSmithKline achieved a sales growth rate of 5% across segments in 2021. Its pharma segment had 10% growth, while its new and specialty medicines segment grew at 26%. GSK's vaccine segment had a 4% growth rate. Also in 2021, the company won FDA approval for Jemperli for endometrial cancer, Xevudy for COVID-19, and Apretude, a long-acting medicine for HIV prevention. Currently, the company has more than 20 vaccines and more than 40 medicines in its pipeline. —BB